New Development in Advanced ROS1-Positive Lung Cancer: FDA Updates Taletrectinib’s Duration of Response to Approximately 50 Months
The FDA approved the Supplemental New Drug Application for taletrectinib in ROS1-positive non-small cell lung cancer. A median duration of response of approximately 50 months (49.7 months) in patients not previously treated with a tyrosine kinase inhibitor has been added to the label, the longest median duration of response reported to date for an FDA-approved ROS1 inhibitor.
17 September 2026 — The U.S. Food and Drug Administration (FDA) approved the Supplemental New Drug Application (sNDA) submitted for taletrectinib (Ibtrozi), used in the treatment of locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC). With this approval, a median duration of response (DOR) reaching approximately 50 months (49.7 months) in patients not previously treated with a tyrosine kinase inhibitor (TKI) was added to the drug's official label.
The decision, which came four months ahead of the target approval date, is based on 51 months of median follow-up data from the TRUST-I clinical study.
Long-Term Data From the TRUST-I Study
The main findings from the study, now reflected in the updated label, are as follows:
- A historic duration of response: In TKI-naive ROS1-positive patients, taletrectinib provided durable clinical benefit lasting more than 4 years (median 49.7 months). This is the longest median duration of response reported to date for an FDA-approved ROS1 inhibitor.
- A consistent safety profile: Despite 51 months of long-term follow-up data, no change was made to the drug's safety profile and no new or unexpected adverse event signal was identified.
ROS1-Positive Lung Cancer and the Role of Taletrectinib
Found in approximately 2% of non-small cell lung cancer cases, ROS1 positivity defines a subgroup at particularly high risk of brain metastasis.
- Around 35% of newly diagnosed metastatic ROS1-positive patients already have brain metastases at the time of diagnosis.
- In previously treated patients, the rate of spread to the central nervous system (CNS) reaches as high as 50%.
Taletrectinib, an orally administered, next generation, selective ROS1 inhibitor that crosses into the central nervous system (CNS-active), represents an important step in managing this challenging patient group, with its high penetration and proven long-term durable efficacy data.
💬 Important Information for Our Patients
Although the updated efficacy durations achieved by this next generation drug with the active substance taletrectinib have been approved and recorded by the U.S. Food and Drug Administration (FDA), the drug is not yet licensed in Turkey. When this innovative agent will enter standard use and when it will arrive in our country is not known at this stage. Our clinic continues to follow such promising developments in the world of oncology closely on behalf of our patients.
Conclusion
The median duration of response of 49.7 months now recorded in the label shows how durable targeted therapy can be in ROS1-positive lung cancer. Given the high risk of brain metastasis in this group, testing for a ROS1 fusion by tissue or liquid biopsy at the time of diagnosis, and bringing in a CNS-active inhibitor early, directly shapes the choice of treatment.
References
- Nuvation Bio. (17 September 2026). Nuvation Bio Announces FDA Approval of Supplemental New Drug Application for IBTROZI (taletrectinib) with Updated Duration of Response in TKI-Naive Advanced ROS1-Positive Non-Small Cell Lung Cancer [Press release].
- U.S. Food and Drug Administration (FDA). FDA approves taletrectinib for ROS1-positive non-small cell lung cancer.